Zevorcabtagene autoleucel (Zevra-cel therapy) approved for R/R multiple myeloma

Zevorcabtagene autoleucel (Zevra-cel therapy) approved for RR multiple myeloma

Share This Post

SHANGHAI, China, April 30, 2024, CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the abstracts of zevorcabtagene autoleucel (R&D code: CT053, an autologous CAR-T product against BCMA) and CT071, an autologous CAR T-cell therapy candidate targeting G protein-coupled receptor class C group 5 member D (GPRC5D), have been accepted for oral presentation and poster presentation, respectively, at the 29th Annual Congress of the European Hematology Association (“EHA”).

 

Abstract Title Abstract Number Publication Type Abstract Release Time (CEST)
PHASE 2 STUDY OF FULLY

HUMAN BCMA-TARGETING

CAR-T CELLS (ZEVORCABTAGENE AUTOLEUCEL) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

S209 Oral presentation May 14, 2024, at 16:00
FIRST-IN-HUMAN STUDY OF GPRC5D-TARGETED CAR T CELLS (CT071)

WITH AN ACCELERATED MANUFACTURING PROCESS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

P941 Poster presentation May 14, 2024 at 16:00

 

About Zevorcabtagene Autoleucel

Zevorcabtagene autoleucel (Zevra-cel therapy) is a fully human, autologous BCMA CAR T-cell product for the treatment of relapsed/refractory multiple myeloma (“R/R MM”). As informed by the NMPA on March 1, 2024, zevorcabtagene autoleucel was approved on February 23, 2024 for the treatment of adult patients with R/R MM who have progressed after at least 3 prior lines of therapy (including a proteasome inhibitor and immunomodulatory agent). CARsgen is conducting a separate Phase 1b/2 LUMMICAR STUDY 2 clinical trial in North America to evaluate the safety and efficacy of zevorcabtagene autoleucel in R/R MM.

Zevorcabtagene autoleucel received Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug designations from the U.S. FDA in 2019, as well as Priority Medicines (PRIME) and Orphan Medicinal Product designations from the European Medicines Agency (EMA) in 2019 and 2020, respectively. Zevorcabtagene autoleucel also received breakthrough therapy designation from the NMPA in 2020.

About CT071

CT071 is a CAR T-cell therapy candidate developed utilizing proprietary CARcelerateTM platform of CARsgen targeting GPRC5D for the treatment of R/R MM or relapsed/refractory plasma cell leukemia (“R/R PCL”). An IIT (NCT05838131) is ongoing in China to evaluate the safety and efficacy of CT071 for the treatment of R/R MM or R/R PCL.

About CARsgen Therapeutics Holdings Limited

CARsgen is a biopharmaceutical company with operations in China and the U.S. and is focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors. CARsgen has established a comprehensive CAR T-cell research and development platform, encompassing target discovery, innovative CAR T-cell development, clinical trials, and commercial-scale production.

CARsgen has internally developed novel technologies and a product pipeline with global rights to address major challenges of CAR T-cell therapies, such as improving the safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs. CARsgen’s mission is to become a global biopharmaceutical leader that brings innovative and differentiated cell therapies to cancer patients worldwide and makes cancer curable.

Forward-looking Statements

All statements in this press release that are not historical fact or that do not relate to present facts or current conditions are forward-looking statements. Such forward-looking statements express the Group’s current views, projections, beliefs and expectations with respect to future events as of the date of this press release. Such forward-looking statements are based on a number of assumptions and factors beyond the group’s control.

As a result, they are subject to significant risks and uncertainties, and actual events or results may differ materially from these forward-looking statements and the forward-looking events discussed in this press release might not occur. Such risks and uncertainties include, but are not limited to, those detailed under the heading “Principal Risks and Uncertainties” in our most recent annual report and interim report and other announcements and reports made available on our corporate website, https://www.carsgen.com.

No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any projections, targets, estimates or forecasts contained in this press release.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy